Across TCGA pan-cancer cohorts, ZNF570 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF570 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher ZNF570 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF570 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
DLBC, ESCA, and UCEC are the cancer types where ZNF570 Mutation most reproducibly stratifies survival.